BR112012021247A2 - solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. - Google Patents
solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma.Info
- Publication number
- BR112012021247A2 BR112012021247A2 BR112012021247-8A BR112012021247A BR112012021247A2 BR 112012021247 A2 BR112012021247 A2 BR 112012021247A2 BR 112012021247 A BR112012021247 A BR 112012021247A BR 112012021247 A2 BR112012021247 A2 BR 112012021247A2
- Authority
- BR
- Brazil
- Prior art keywords
- levofloxacin
- ophthalmic solution
- solvate
- eye infection
- salt
- Prior art date
Links
- 208000001860 Eye Infections Diseases 0.000 title abstract 7
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title abstract 7
- 229960003376 levofloxacin Drugs 0.000 title abstract 7
- 208000011323 eye infectious disease Diseases 0.000 title abstract 6
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 4
- 239000002997 ophthalmic solution Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000012453 solvate Substances 0.000 title abstract 4
- 229940114474 levofloxacin ophthalmic solution Drugs 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 3
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-040281 | 2010-02-25 | ||
| JP2010040281 | 2010-02-25 | ||
| PCT/JP2010/072685 WO2011104981A1 (ja) | 2010-02-25 | 2010-12-16 | レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012021247A2 true BR112012021247A2 (pt) | 2018-04-03 |
Family
ID=44506417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021247-8A BR112012021247A2 (pt) | 2010-02-25 | 2010-12-16 | solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120316158A1 (https=) |
| EP (1) | EP2540299B1 (https=) |
| JP (3) | JP5600056B2 (https=) |
| KR (2) | KR20130043611A (https=) |
| CN (1) | CN102770141A (https=) |
| BR (1) | BR112012021247A2 (https=) |
| CA (1) | CA2791190C (https=) |
| EA (1) | EA201290827A1 (https=) |
| ES (1) | ES2568647T3 (https=) |
| MX (1) | MX349603B (https=) |
| MY (1) | MY183483A (https=) |
| NZ (1) | NZ602126A (https=) |
| PH (2) | PH12012501674A1 (https=) |
| SG (1) | SG183427A1 (https=) |
| TW (1) | TWI488627B (https=) |
| WO (1) | WO2011104981A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130043611A (ko) * | 2010-02-25 | 2013-04-30 | 다이이찌 산쿄 가부시키가이샤 | 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도 |
| CN103550144B (zh) * | 2013-10-25 | 2015-10-14 | 深圳朗欧医药集团有限公司 | 盐酸左氧氟沙星组合物注射液及其制备方法 |
| JP6363833B2 (ja) * | 2013-11-22 | 2018-07-25 | ナノシータ株式会社 | 薄膜状高分子構造体 |
| CN104606198A (zh) * | 2015-01-09 | 2015-05-13 | 周元铎 | 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用 |
| IT201900005280A1 (it) * | 2019-04-05 | 2020-10-05 | Ntc S R L | Composizione otologica |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3038722B2 (ja) | 1989-06-23 | 2000-05-08 | 日本電気株式会社 | 接合型電界効果トランジスタ |
| JP3192290B2 (ja) | 1993-08-04 | 2001-07-23 | カネボウ株式会社 | ポリエステル製耐熱ボトル |
| US7629458B2 (en) * | 2001-10-03 | 2009-12-08 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and hemihydrate thereof |
| ES2292844T3 (es) * | 2001-11-30 | 2008-03-16 | Lg Life Sciences Ltd. | Utilizacion de gemifloxacina o sus sales con un antibiotico b-lactamico para la preparacion de medicamentos. |
| US20050009836A1 (en) * | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| WO2005000307A1 (en) * | 2003-06-26 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition containing quinolones and method of use |
| MX2008010222A (es) * | 2006-02-10 | 2008-10-17 | Pari Pharma Gmbh | Antibioticos nebulizados para terapia de inhalacion. |
| WO2008005276A2 (en) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| KR20130043611A (ko) * | 2010-02-25 | 2013-04-30 | 다이이찌 산쿄 가부시키가이샤 | 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도 |
-
2010
- 2010-12-16 KR KR1020127024069A patent/KR20130043611A/ko not_active Ceased
- 2010-12-16 CN CN2010800646540A patent/CN102770141A/zh active Pending
- 2010-12-16 EP EP10846644.2A patent/EP2540299B1/en not_active Not-in-force
- 2010-12-16 EA EA201290827A patent/EA201290827A1/ru unknown
- 2010-12-16 MY MYPI2012003769A patent/MY183483A/en unknown
- 2010-12-16 WO PCT/JP2010/072685 patent/WO2011104981A1/ja not_active Ceased
- 2010-12-16 NZ NZ602126A patent/NZ602126A/xx not_active IP Right Cessation
- 2010-12-16 JP JP2010280325A patent/JP5600056B2/ja active Active
- 2010-12-16 KR KR1020177015979A patent/KR20170070265A/ko not_active Ceased
- 2010-12-16 ES ES10846644.2T patent/ES2568647T3/es active Active
- 2010-12-16 MX MX2012009844A patent/MX349603B/es active IP Right Grant
- 2010-12-16 CA CA2791190A patent/CA2791190C/en not_active Expired - Fee Related
- 2010-12-16 BR BR112012021247-8A patent/BR112012021247A2/pt not_active Application Discontinuation
- 2010-12-16 PH PH1/2012/501674A patent/PH12012501674A1/en unknown
- 2010-12-16 US US13/580,931 patent/US20120316158A1/en not_active Abandoned
- 2010-12-16 PH PH1/2016/501747A patent/PH12016501747B1/en unknown
- 2010-12-16 SG SG2012061842A patent/SG183427A1/en unknown
- 2010-12-28 TW TW099146206A patent/TWI488627B/zh not_active IP Right Cessation
-
2012
- 2012-03-12 JP JP2012054761A patent/JP2012162532A/ja active Pending
-
2013
- 2013-08-16 JP JP2013169146A patent/JP5674882B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201290827A1 (ru) | 2013-03-29 |
| TWI488627B (zh) | 2015-06-21 |
| KR20130043611A (ko) | 2013-04-30 |
| EP2540299B1 (en) | 2016-04-13 |
| ES2568647T3 (es) | 2016-05-03 |
| SG183427A1 (en) | 2012-09-27 |
| PH12016501747B1 (en) | 2022-06-22 |
| KR20170070265A (ko) | 2017-06-21 |
| JP5600056B2 (ja) | 2014-10-01 |
| TW201129364A (en) | 2011-09-01 |
| CA2791190C (en) | 2017-12-12 |
| JP2011195564A (ja) | 2011-10-06 |
| US20120316158A1 (en) | 2012-12-13 |
| EP2540299A4 (en) | 2013-07-24 |
| JP5674882B2 (ja) | 2015-02-25 |
| JP2012162532A (ja) | 2012-08-30 |
| MX2012009844A (es) | 2012-09-21 |
| PH12016501747A1 (en) | 2019-02-11 |
| MY183483A (en) | 2021-02-20 |
| AU2010346703A1 (en) | 2012-09-20 |
| NZ602126A (en) | 2013-10-25 |
| HK1177887A1 (en) | 2013-08-30 |
| MX349603B (es) | 2017-08-03 |
| JP2013241464A (ja) | 2013-12-05 |
| EP2540299A1 (en) | 2013-01-02 |
| PH12012501674A1 (en) | 2012-11-05 |
| CA2791190A1 (en) | 2011-09-01 |
| CN102770141A (zh) | 2012-11-07 |
| WO2011104981A1 (ja) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| BR112018008965A2 (pt) | terapia de reposição de plasminogênio para deficiência de plasminogênio | |
| BR112013017875A2 (pt) | introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas | |
| BR112012021247A2 (pt) | solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. | |
| MX2015009269A (es) | Composiciones farmaceuticas que comprenden donadores de nitroxilo. | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| BR112021024716A2 (pt) | Ruptura de biofilme | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BRPI0916885B8 (pt) | composição farmacêutica | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| GB2541840A (en) | Ophthalmic composition for the treatment of ocular infection | |
| BR112019024082A2 (pt) | Métodos de tratamento para distonia cervical | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| CL2021001222A1 (es) | Composición nutricional infantil para usar en el mejoramiento de la maduración pancreática y la biosíntesis de insulina | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
| BR112018009413A2 (pt) | formulação oral sólida e método para preparar a formulação oral sólida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |